# Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury

> **NCT07518303** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Jianfeng Xie** · enrollment: 1162 (estimated)

## Conditions studied

- Sepsis
- Acute Kidney Injury
- Continuous Renal Replacement Therapy (CRRT)

## Interventions

- **DRUG:** Citrate anticoagulation
- **DRUG:** Nafamostat Mesylate

## Key facts

- **NCT ID:** NCT07518303
- **Lead sponsor:** Jianfeng Xie
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 1162 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07518303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07518303, "Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07518303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*